Follow-up to evaluate the the immunogenicity and safety of GSK Biologicals' MMRV [MMR-varicella zoster virus vaccine] vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix [Measles mumps and rubella virus vaccine] and Varilrix [varicella zoster virus vaccine live]

Trial Profile

Follow-up to evaluate the the immunogenicity and safety of GSK Biologicals' MMRV [MMR-varicella zoster virus vaccine] vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix [Measles mumps and rubella virus vaccine] and Varilrix [varicella zoster virus vaccine live]

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine; Varicella zoster virus vaccine live
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Feb 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top